Avicanna's CEO Touts Q3 As 'Most Successful Quarter To Date' As It Posts Record Results, Expands Into 12th International Market
CBD-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE:0NN) reported its third-quarter financial results Friday, revealing a gross revenue increase of 24% sequentially and 260% compared to the first three months of 2021 to roughly CA$1,007,033 ($987,967)